ABBOTT LABORATORIES acquired BASF's pharmaceutical business (Knoll) for approximately $6.9 billion in cash, a transaction completed in March 2001, structured as all cash.
BASF's pharmaceutical business (Knoll) operates in Pharmaceuticals, is based in Ludwigshafen, Germany (global operations). BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA).
Expanded Abbott's global pharmaceutical operations and added a research pipeline that included the antibody Abbott later developed into HUMIRA.
Global pharmaceutical scale plus a pipeline antibody that became one of the best-selling drugs in history. Integrated into Abbott's pharmaceutical business
Advisory firms were not disclosed for this transaction.